Novartis AG (NOVN) - Financial and Strategic SWOT Analysis Review

October 2021 | 101 pages | ID: N425DFFCE9DEN
GlobalData

Abstracts

Novartis AG (NOVN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Novartis AG (Novartis) is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.

Novartis AG Key Recent Developments

Oct 07,2021: Novartis to present broad range of portfolio data at ECTRIMS, reinforcing long-standing commitment to people living with multiple sclerosis
Sep 30,2021: Novartis accelerates efforts toward ESG targets to increase access to medicines, improve health equity and achieve net-zero carbon emissions
Aug 26,2021: The next generation of implantable drug delivery devices goes remote onboard the ISS
Jul 21,2021: Novartis Announces Q2 2021 Financial Results
Jul 21,2021: Novartis delivered strong Q2 performance, driven by momentum of key growth brands

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Novartis AG - Key Facts
Novartis AG - Key Employees
Novartis AG - Key Employee Biographies
Novartis AG - Major Products and Services
Novartis AG - History
Novartis AG - Company Statement
Novartis AG - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture

SECTION 2 – COMPANY ANALYSIS

Company Overview
Novartis AG - Business Description
Business Segment: Innovative Medicines
Overview
Performance
Key Stats
Business Segment: Sandoz
Overview
Performance
Key Stats
Geographical Segment: Asia/Africa/Australasia
Performance
Geographical Segment: Canada and Latin America
Performance
Geographical Segment: Europe
Performance
Geographical Segment: The US
Performance
R&D Overview
Novartis AG - Corporate Strategy
Novartis AG - SWOT Analysis
SWOT Analysis - Overview
Novartis AG - Strengths
Novartis AG - Weaknesses
Novartis AG - Opportunities
Novartis AG - Threats
Novartis AG - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES, POWER FINANCIAL DEALS AND ALLIANCES

Novartis AG, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Novartis AG, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Novartis AG, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Oct 07, 2021: Novartis to present broad range of portfolio data at ECTRIMS, reinforcing long-standing commitment to people living with multiple sclerosis
Sep 30, 2021: Novartis accelerates efforts toward ESG targets to increase access to medicines, improve health equity and achieve net-zero carbon emissions
Aug 26, 2021: The next generation of implantable drug delivery devices goes remote onboard the ISS
Jul 21, 2021: Novartis Announces Q2 2021 Financial Results
Jul 21, 2021: Novartis delivered strong Q2 performance, driven by momentum of key growth brands
Jun 28, 2021: Novartis appoints Rob Kowalski as Chief People & Organization Officer
Jun 25, 2021: Novartis Hellas S.A.C.I. and Alcon agree to pay over $233 million combined to resolve criminal FCPA cases
Jun 23, 2021: Novartis and Hewlett Packard Enterprise join forces to advance Novartis global health efforts
Jun 23, 2021: Novartis and Hewlett Packard Enterprise join forces to advance Novartis global health efforts
Jun 21, 2021: Novartis, Bayer and Boehringer Ingelheim to showcase their commitment to a reimagined pharma industry

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Novartis AG, Key Facts
Novartis AG, Key Employees
Novartis AG, Key Employee Biographies
Novartis AG, Major Products and Services
Novartis AG, History
Novartis AG, Subsidiaries
Novartis AG, Joint Venture
Novartis AG, Key Competitors
Novartis AG, Ratios based on current share price
Novartis AG, Annual Ratios
Novartis AG, Annual Ratios (Cont...1)
Novartis AG, Annual Ratios (Cont...2)
Novartis AG, Interim Ratios
Novartis AG, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Novartis AG, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Novartis AG, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Novartis AG, Performance Chart (2016 - 2020)
Novartis AG, Ratio Charts
Novartis AG, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Novartis AG, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021